ESMO Press Office

The ESMO Press Office welcomes media professionals interested in reporting on cancer.

For enquiries please contact us on:
media@esmo.org

ESMO 2018 640x90 Hashtag

 

The ESMO Press Office is happy to welcome media representatives in Munich!

 

A dedicated and equipped press room is located in the ICM - first floor and is accessible on:

Opening day Time
Thursday, 18 October 2018 14:00 - 18:00
Friday, 19 October 2018 08:30 - 18:00
Saturday, 20 October 2018 07:30 - 18:00
Sunday, 21 October 2018 07:30 - 18:00
Monday, 22 October 2018 07:30 - 18:00
Tuesday, 23 October 2018 07:30 - 13:00

Please find below the ESMO press programme details and the schedules of all press activities, including ESMO press briefings and ESMO expert corners, accessible onsite to accredited media representatives*.    *Accordingly to the ESMO Media Policy.

Publication schedule for accepted abstracts
  1. Abstracts accepted for presentation at ESMO 2018 as Poster – suffix P or TiP – will be published online via the ESMO website at 00:05 CEST on Tuesday, 9 October 2018.
  2. Abstracts accepted for presentation at ESMO 2018 as Proffered Paper (oral presentation) or Poster Discussion will be published online via the ESMO website at 12:00 CEST on Friday, 19 October 2018.
  3. All Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.
  4. Abstracts and Late-breaking abstracts selected for inclusion in the ESMO 2018 press programme, will be published accordingly to the schedule reported in the section below.
ESMO Press Programme : press releases schedule

The following abstracts are included in the ESMO 2018 press programme and will be accompanied by a press release.

Please note that for some them, the publication schedule may differ from the general one posted above.

Upon publication, direct links to the press releases will be added.

    FPN Title Author name Embargo lift and press release distribution date/time Press release
1891O_PR Mutational Landscape of Metastatic Cancers Discovered from Prospective Clinical Sequencing at Community Practice Cancer Program R. Alvarez Tuesday, 9 October 2018 at 00:05 CEST Press release
1655P_PR The use of complementary and alternative medicine (CAM) in sarcoma patients K. Sungu-Winkler

 

Wednesday, 10 October 2018 at 00:05 CEST

 

Press release

 

1632P_PR Characterizing the risk of drug-drug interactions in sarcoma treated patients: role of pharmacist integration A. Bellesoeur
360P_PR Breast cancer in Twitter: a real-world data exploratory study R. Sanchez Bayona Friday, 12 October 2018 at 00:05 CEST Press release
1576P_PR Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation? E. Winkler Tuesday, 16 October 2018 at 00:05 CEST  
185O_PR Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort B. Pistilli Friday, 19 October 2018 at 00:05 CEST  
619PD_PR Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials M. Davidson Friday, 19 October 2018 at 00:05 CEST  
1555O_PR Magnitude of Clinical Benefit of Cancer Drugs and Time to Health Technology Assessment (HTA) Decisions in Europe T. Hwang Friday, 19 October 2018 at 10:45 CEST  
191PD_PR 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio P. Conte

 

Friday, 19 October 2018 at 16:00 CEST

 

 

 

LBA12_PR PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results C. Hulme
1213P_PR Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV) A. Gobert Saturday, 20 October 2018 at 00:05 CEST  
251P_PR Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients J. Martin-Babau Saturday, 20 October 2018 at 00:05 CEST  
1777P_PR Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study Q. Tran

 

Saturday, 20 October 2018 at 00:05 CEST

 

 
1480P_PR Effects of Physical Exercise in non-operable lung cancer patients undergoing palliative treatment E. Wiskemann  
1684PD_PR Physical Activity (PA) and patterns of Quality of Life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC) A. Di Meglio

 

Saturday, 20 October 2018 at 00:05 CEST

 

 
1753P_PR Benefits of Physical Activity and Sport integrated into the care pathway of oncology patient L. Vanlemmens  
1350PD_PR Social and behavioral indicators of undergoing a screening test for lung cancer S. Couraud

 

 

Saturday, 20 October 2018 at 00:05 CEST

 

 

 

 

 

 

 

 

 

962P_PR Indicators of non-participation in cervical cancer screening: results from the EDIFICE 6 survey T. de La Motte Rouge
1594P_PR Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey J-F. Morere
525P_PR Profile of individuals who never undergo colorectal cancer screening J. Viguier
LBA14_PR The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid F. Perrone Saturday, 20 October 2018 at 15:00 CEST  
LBA3_PR Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase III SOLAR-1 trial F. André Saturday, 20 October 2018 at 16:30 CEST  
LBA1_PR IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) P. Schmid Saturday, 20 October 2018 at 16:30 CEST  
LBA2_PR Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3 M. Cristofanilli Saturday, 20 October 2018 at 16:30 CEST  
283O_PR Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer Z. Jiang Saturday, 20 October 2018 at 16:30 CEST  
424P_PR Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth? A. Vozy Sunday 21 October 2018 at 00:05 CEST  
1682O_PR Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving Fluropyrimidines and/or Irinotecan based therapy A. Sharma Sunday 21 October 2018 at 00:05 CEST  
294PD_PR Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program J-S. Frenel

 

 

 

Sunday 21 October 2018 at 00:05 CEST

 

 

 

 

 

273PD_PR Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients M. Reinisch
293PD_PR Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial C. Zamagni
LBA48_PR CTONG 1103:Erlotinib versus Gemcitabine plus Cisplatin as Neo-adjuvant Treatment for Stage IIIA –N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study W-Z. Zhong Sunday 21 October 2018 at 09:15 CEST  
LBA6_PR JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) R. Motzer Sunday 21 October 2018 at 16:30 CEST  
LBA5_PR Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476) C. Parker Sunday 21 October 2018 at 16:30 CEST  
LBA7_PR Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial K. Moore Sunday 21 October 2018 at 16:30 CEST  
LBA18_PR Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) H-J. Lenz Monday, 22 October 2018 at 09:15 CEST  
LBA37_PR Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer M. Chalabi Monday, 22 October 2018 at 011:15 CEST  
LBA8_PR KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) B. Burtness Monday, 22 October 2018 at 16:30 CEST  
LBA9_PR Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy H. Mehanna Monday, 22 October 2018 at 16:30 CEST  
Appointments for media representatives: press briefings and expert corner

Press  briefings

Times of press events may be subject to changes.

Abstracts presented in the press briefings are under embargo, content must not be disclosed until the official embargo lifts (please refer to the schedule above)

 

Friday, 19 Oct 2018 Saturday, 20 Oct 2018 Sunday, 21 Oct 2018 Monday, 22 Oct 2018

Opening press conference
10:45-11:30
Securing access to optimal cancer care

Moderator
Jo Browning

ESMO President
Josep Tabernero

ESMO2018
Scientific Chair
Solange Peters

ESMO2018
Press Officer
Pilar Garrido

1555O_PR
HTA decisions in Europe
Kerstin Vokinger

Press briefing 1
08:15-09:00
Breast cancer

Moderator
Giuseppe Curigliano

Commentators
Giuseppe Curigliano and Nadia Harbeck

LBA1_PR
IMPassion130
Peter Schmid

LBA3_PR
SOLAR-1
Fabrice André

LBA2_PR
PALOMA-3
Massimo Cristofanilli

Press briefing 3
08:15-09:00
Prostate and kidney cancers

Moderator
Ignacio Duran

Commentators
John Haanen and
Ignacio Duran

LBA6_PR
Javelin Renal 101
Robert Motzer

LBA5_PR
Stampede
Chris Parker

Press briefing 4
08:15-09:00
Head and neck cancers

Moderator
Branislav Bystricky

Commentators
Branislav Bystricky and Jean-Pascal Machiels

LBA8_PR
Keynote-048
Barbara Burtness

LBA9_PR
cetuximab vs cisplatin
Hisham Mehanna

 

 Press briefing 2
11:15-12:00
Ovarian cancer

Moderator
Jo Browning

Introduction
Susana Banerjee

LBA7_PR
SOLO1
Kathleen Moore

Commentator
Jonathan Ledermann

ESMO Patient guides on ovarian cancer
Nicoletta Colombo

World Ovarian Cancer Coalition
Clara MacKay

   

 

Expert corners

Times may be subject to changes. The experts involved in the corners are not responsible for the embargoed information shared with journalists. Journalists must always verify the embargo of every abstract before disclosing any content.

The expert corners take place twice daily from Saturday to Monday in the Press Room (ICM, 1st floor).

The final Q&A with the members of the Press Committee takes place on Tuesday morning in the Press Conference Room (Press West Entrance, 2nd floor)

Saturday, 20 Oct. 2018 Sunday, 21 Oct. 2018 Monday, 22 Oct. 2018 Tuesday, 23 Oct. 2018

Expert Corner
11:00-12:00

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Gastrointestinal tumours, gynaecological cancers, central nervous system tumours
Branislav Bystricky, Slovakia

Breast cancer
Carmen Criscitiello, Italy

Genitourinary tumours
Ignacio Duran, Spain

Gastrointestinal tumours (not colorectal cancer) and neuroendocrine tumours
Angela Lamarca, UK

 

 

 

 

 

 

 

 

 

 

 

 

 

Expert Corner
11:00-12:00

Lung cancer, immunotherapy
Stefan Zimmermann, Switzerland

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Lung cancer and public policy issues
Marina Garassino, Italy

Gastrointestinal tumours, gynaecological cancers, central nervous system tumours
Branislav Bystricky, Slovakia

Breast cancer and early drug development
Giuseppe Curigliano, Italy

Early clinical trials, biomarkers, precision medicine and colorectal cancer
Rodrigo Dienstmann, Spain

Genitourinary tumours
Ignacio Duran, Spain

Drug development, urogenital tumours, thoracic tumours
Markus Joerger, Switzerland

 

 

 

 

 

Expert Corner
11:00-12:00

Lung cancer, immunotherapy
Benjamin Besse, France

Lung cancer and public policy issues
Marina Garassino, Italy

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Gastrointestinal tumours, gynaecological cancers, central nervous system tumours
Branislav Bystricky, Slovakia

Breast cancer
Carmen Criscitiello, Italy

Breast cancer and early drug development
Giuseppe Curigliano, Italy

Early clinical trials, biomarkers, precision medicine and colorectal cancer
Rodrigo Dienstmann, Spain

 

 

 

 

 

 

 

 

Q&A session with ESMO Press and Media Affairs Committee members
08:15-09:00 

Lung cancer, immunotherapy
Stefan Zimmermann, Switzerland

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Breast cancer
Carmen Criscitiello, Italy

Breast cancer and early drug development
Giuseppe Curigliano, Italy

Breast cancer, supportive care, survivorship issues
Matteo Lambertini, Belgium

Gastrointestinal tumours, gynaecological cancers, central nervous system tumours
Branislav Bystricky, Slovakia

Early clinical trials, biomarkers, precision medicine and colorectal cancer
Rodrigo Dienstmann, Spain

 

 

 

 

Saturday, 20 Oct. 2018 Sunday, 21 Oct. 2018 Monday, 22 Oct. 2018

Expert Corner
14:30-15:30 

Lung cancer, immunotherapy
Benjamin Besse, France

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Breast cancer
Carmen Criscitiello, Italy

Breast cancer and early drug development
Giuseppe Curigliano, Italy

Breast cancer, supportive care, survivorship issues
Matteo Lambertini, Belgium

Gastrointestinal tumours (not colorectal cancer) and neuroendocrine tumours
Angela Lamarca, UK

 

 

 

 

Expert Corner
14:30-15:30 

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Breast cancer
Carmen Criscitiello, Italy

Breast cancer, supportive care, survivorship issues
Matteo Lambertini, Belgium

Genitourinary tumours
Ignacio Duran, Spain

Gastrointestinal tumours (not colorectal cancer) and neuroendocrine tumours
Angela Lamarca, UK

 

 

 

 

 

 

 

Expert Corner
14:30-15:30 

Lung and other thoracic tumours, immunotherapy
Alessandra Curioni-Fontecedro, Switzerland

Breast cancer
Carmen Criscitiello, Italy

Breast cancer and early drug development
Giuseppe Curigliano, Italy

Breast cancer, supportive care, survivorship issues
Matteo Lambertini, Belgium

Drug development, urogenital tumours, thoracic tumours
Markus Joerger, Switzerland 

Early clinical trials, biomarkers, precision medicine and colorectal cancer
Rodrigo Dienstmann, Spain

 

 

 

 

See all the ESMO press releases              ESMO on Twitter             

ESMO YouTube Channel ESMO Flickr Stream

Visit our YouTube Channel and get access to our latest videos.

Visit our  Flickr Stream and browse through our entire photo library

ESMO 2017 - Day 1

Policies

Related Links